SEP 08, 2018 1:54 PM PDT

Protein Associated With ALS Inspires Drug Treatments

WRITTEN BY: Nouran Amin

Neurodegenerative diseases, such as degenerative ataxia or amyotrophic lateral sclerosis (ALS), will progressively cause an affected individual to develop the inability to move and think. Unfortunately, there exists only few treatments. However, findings from a recent research study published in Nature Communications have found potential approaches for developing therapeutic drugs, opening the doors for more treatments.

The researchers, from the University of Utah Health, have identified a protein called ‘Staufen1’ which accumulates in the cells of patients suffering from degenerative ataxia or ALS, also known as Lou Gehrig's disease. "Staufen was first discovered in the fruit fly and has been studied for 30 years, but it had never been connected to anything related to disease," says Stefan Pulst M.D., Dr. Med., chair of Neurology at U of U Health and senior researcher on the study. "This is a novel finding." Removing staufen1 protein from model mice with neurodegenerative diseases was shown to improve the exhibited disease symptoms including motor function.

Credit: Readers Digest

The results suggest that developing drugs that target Staufen1 could have a therapeutic potential in patients. "This is a completely new avenue for thinking about neurodegenerative diseases," explains Pulst. "A protein that had never been known to be involved in neurodegeneration is now a great target for drug treatments."

Previous studies did not see the protein as a problem in neurodegenerative disease until researchers found a relationship between Staufen1 and ataxia, a rare condition causing loss of movement. More specifically, the scientists discovered that Staufen1 binds with another protein called ‘Ataxin2’ which is a risk factor for ALS and responsible for ataxia. Future research will aim on determining whether drugs or other therapeutics that can decrease Staufen1 can be developed to treat other diseases. Additionally, the research “connects Staufen1 to the emerging concept that neurodegenerative diseases are linked to malfunctions in the way cells cope with cellular stress.”

“One implication”, says co-author Daniel Scoles, Ph.D., associate professor of Neurology at U of U Health, “is that Staufen1-targeted therapies could work against a number of disorders in which stress granules emerge, although it remains to be determined whether the aggregates themselves lead to disease. Our results put the stress granule in focus as a structure to target in disease."

Source: University of Utah, Nature Communications

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
APR 11, 2020
Drug Discovery & Development
APR 11, 2020
Remdesivir Improves COVID-19 Symptoms in 68% of Patients in Early Study
An early analysis of remdesivir, a drug developed by pharmaceutical firm Gilead, has shown that it may have improved sev ...
APR 15, 2020
Neuroscience
APR 15, 2020
How Magic Mushrooms Restructure the Brain
For some time now, researchers have suspected that psilocybin, the hallucinogen chemical present in ‘magic mushroo ...
APR 21, 2020
Health & Medicine
APR 21, 2020
How to Read COVID-19 News (Without Going Crazy)
  It can feel like COVID-19 news is consuming the country, and taking all the toilet paper and N95-masks with it. N ...
MAY 02, 2020
Drug Discovery & Development
MAY 02, 2020
Glioblastoma Treatment Using Schizophrenic Drug Plus Radiation
A therapeutic used for the treatment of schizophrenia could be a gateway for targeting glioblastoma, one of the deadlies ...
MAY 25, 2020
Cancer
MAY 25, 2020
Using Transcription Factors to Predict Bladder Cancer Prognosis
Bladder cancer is a rare form of cancer, with a relatively high recovery rate. Recurrence is still an issue; however, wi ...
MAY 28, 2020
Cancer
MAY 28, 2020
The Oncogenic Hazard of a Potential Alzheimer's Treatment
Breast cancer remains one of the most common cancers around the world. Triple-Negative Breast Cancer (TNBC) is a sub-typ ...
Loading Comments...